Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China

Key Points

• The study aims to evaluate the safety of the Haemophilus influenzae Type b conjugate vaccine in young children after it has been introduced to the market.
• Conducted post-marketing safety surveillance in Jiangsu, China
• Monitored adverse reactions in children aged 3 months to 5 years
• Analyzed data from two surveillance systems
• No serious adverse reactions reported
• Favorable safety profile confirmed with the Hib conjugate vaccine
• No safety-associated risks identified over the surveillance period